![]() Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a phase 1b study. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. 2019 133(1):7-17.ĭiNardo CD, Pratz KW, Letai A, et al. Voir le profil de Ana Maria Amaya Fajardo sur LinkedIn, le plus grand réseau professionnel mondial. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. Acute myeloid leukemia: 2021 update on risk-stratification and management. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. © 2021 by The American Society of Hematology. ![]() Specific variables, such as RUNX1 mutations, reported here for the first time, can be identified that favor ven/aza or IC, helping to guide treatment decisions for patients who may be eligible candidates for either therapy. However, in a propensity-matched cohort of patients with equivalent baseline factors, there was a trend toward favorable OS for ven/aza. In conclusion, patients receiving IC have improved OS compared with those receiving ven/aza. ![]() Her excellent and well-presented research over several months was very helpful in conducting due diligence and refining the business model prior to a new service launch. In the propensity-matched cohort analyzing OS, older age, adverse risk, and RUNX1 mutations favored ven/aza over IC, whereas intermediate risk favored IC over ven/aza. Ana Maria conducted confidential and market-sensitive research ultimately for one of GPGs publicly-traded company clients. AML M5 favored response to IC over ven/aza. Variables that favored response to ven/aza over IC included older age, secondary AML, and RUNX1 mutations. There are 200+ professionals named 'Maria Amaya', who use LinkedIn to exchange information, ideas, and opportunities. A propensity-matched cohort was used to compare outcomes in the setting of equivalent baseline variables, and when matched for age, biological risk, and transplantation, the median OS was 705 days for IC compared with not reached for ven/aza (P =. View the profiles of professionals named 'Maria Amaya' on LinkedIn. The median overall survival (OS) was 884 days for IC compared with 483 days for ven/aza (P =. The response rates were 76.9% for ven/aza and 70.5% for IC. We retrospectively analyzed patients with newly diagnosed AML who received ven/aza (n = 143) or IC (n = 149) to compare outcomes, seek variables that could predict response to 1 therapy or the other, and ascertain whether treatment recommendations could be refined. Some patients who are IC candidates instead receive ven/aza. Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy (IC). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |